Clinical Trials Logo

Filter by:
NCT ID: NCT00256880 Completed - Clinical trials for Carcinoma, Renal Cell

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

NCT ID: NCT00256867 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study In Patients With Type 2 Diabetes Mellitus

Start date: August 18, 2005
Phase: Phase 3
Study type: Interventional

This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.

NCT ID: NCT00256750 Completed - Clinical trials for Kidney Transplantation

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

BENEFIT
Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.

NCT ID: NCT00256711 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

Phase II Iressa Versus Vinorelbine (INVITE)

Start date: July 2004
Phase: Phase 2
Study type: Interventional

This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSAâ„¢) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.

NCT ID: NCT00256126 Completed - Clinical trials for Growth Hormone Deficiency

Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

Start date: May 31, 2005
Phase: Phase 4
Study type: Interventional

The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.

NCT ID: NCT00256087 Completed - Critical Illness Clinical Trials

The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients

Start date: January 2005
Phase: N/A
Study type: Interventional

To assess the effect of addition of probiotic Lactobacilli to standard enteral feeding on infection rates and feeding efficacy in critically ill patients. The study hypothesis is that critically ill patients who receive the addition of probiotic lactobacilli to the enteral feed will lead to a reduced rate of hospital acquired infections. The null hypothesis is that there will be no significant difference in the rate of hospital acquired infection in critically ill patients who receive enteral feeding with or without the addition of probiotic Lactobacilli.

NCT ID: NCT00256048 Completed - Critically Ill Clinical Trials

Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

Start date: May 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if naso-jejunal feeding (feeding beyond the stomach) improves the efficacy of enteral feeding (feeding into the gut) in critically ill patients. The study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.

NCT ID: NCT00254579 Completed - Refractory Melanoma Clinical Trials

Study of CP-675,206 in Refractory Melanoma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

NCT ID: NCT00254215 Completed - Obesity Clinical Trials

Glycemic Load, Weight Loss and Cardiovascular Disease Risk

Start date: March 2002
Phase: Phase 1
Study type: Interventional

To investigate the hypothesis that reducing the glycemic load of the diet will improve changes in body composition and cardio-vascular risk factors. The study compares a conventional reduced-fat, high carbohydrate diet with 3 means of reducing glycemic load: changing the carbohydrates to low-GI choices, replacing some of the carbohydrate with protein, or combining both effects to produce the lowest glycemic load.

NCT ID: NCT00253968 Completed - Insomnia Clinical Trials

Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia

GEMS
Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia. The patients suffering from that condition frequently wake up during the night, their sleep is nonrestorative and they suffer from a significant distress or impairment in their daily activities consecutive to insomnia.